| __timestamp | Neurocrine Biosciences, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 79838000 |
| Thursday, January 1, 2015 | 33800000 | 121816000 |
| Friday, January 1, 2016 | 35900000 | 117633000 |
| Sunday, January 1, 2017 | 1254000 | 4577000 |
| Monday, January 1, 2018 | 4889000 | 12670000 |
| Tuesday, January 1, 2019 | 7400000 | 12135000 |
| Wednesday, January 1, 2020 | 10100000 | 18942000 |
| Friday, January 1, 2021 | 14300000 | 32328000 |
| Saturday, January 1, 2022 | 23200000 | 44678000 |
| Sunday, January 1, 2023 | 39700000 | 65486000 |
| Monday, January 1, 2024 | 34000000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. Neurocrine Biosciences, Inc. and PTC Therapeutics, Inc. have shown contrasting trends over the past decade. From 2014 to 2023, Neurocrine's cost of revenue has seen a steady increase, peaking at approximately $39.7 million in 2023, a growth of over 175% from 2014. In contrast, PTC Therapeutics experienced a more volatile trajectory, with costs fluctuating significantly, reaching a high of around $121.8 million in 2015 before stabilizing at $65.5 million in 2023. This divergence highlights the strategic differences in managing operational expenses. As investors and analysts delve into these figures, the insights gleaned can guide future investment decisions and strategic planning in the biotech sector.
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.